EC
RDY icon

EntryPoint Capital’s Dr. Reddy's Laboratories RDY Stock Holding History

EntryPoint Capital’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,240
Closed -$18.2K – 1770
2024
Q1 		$18.2K Sell
1,240
-2,590
-68% -$37.8K 0.02% 1127
2023
Q4 		$53.3K Buy
+3,830
New +$51.2K 0.05% 682

Other funds holding RDY

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
Aikya Investment Management London, United Kingdom $341M AUM 28.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

EntryPoint Capital's RDY Position: Q2 2024 in Review

EntryPoint Capital sold out of Dr. Reddy's Laboratories (RDY) in Q2 2024, closing a stake of 1,240 shares — an estimated $18.2K sold.

EntryPoint Capital first reported a position in RDY in Q4 2023 and held it in 2 quarters. The position peaked at $53.3K in Q4 2023. 222 funds tracked by Wall St. Rank hold RDY as of Q2 2024.

  • EntryPoint Capital reported no remaining Dr. Reddy's Laboratories position as of Q2 2024 after selling out during the quarter.
  • EntryPoint Capital sold 1,240 Dr. Reddy's Laboratories shares in Q2 2024, an estimated $18.2K.
  • EntryPoint Capital first reported a position in Dr. Reddy's Laboratories in Q4 2023 and held it in 2 quarters.
  • EntryPoint Capital's Dr. Reddy's Laboratories position peaked at $53.3K in Q4 2023.
  • 222 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q2 2024.

Based on EntryPoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.